je.st
news
Tag: amgen
Amgen pays $290M to exit osteoporosis drug deal
2014-04-04 06:17:49| Biotech - Topix.net
Amgen will pay $290 million to end its collaboration with British drugmaker GlaxoSmithKline to commercialize the osteoporosis drug denosumab in certain markets outside the U.S. Amgen will pay $290 million to end its collaboration with British drugmaker GlaxoSmithKline to commercialize the osteoporosis drug denosumab in certain markets outside the ... (more)
Amgen: Allowing Dividend Growth Investors To Capitalize On The Biotech Sell-Off
2014-04-01 12:54:12| Biotech - Topix.net
In my opinion, Amgen is the only viable option for a conservative income investor looking for large-cap exposure to biotech.
Tags: growth
allowing
investors
biotech
Amgen vaccine triggers immune response in advanced melanoma -study
2014-03-15 09:04:30| Biotech - Topix.net
An experimental Amgen Inc cancer vaccine used to treat advanced melanoma, the deadliest form of skin cancer, proved effective in a late-stage study in shrinking tumors in a way that suggests the drug triggered the intended systemic immune response, according to data presented on Friday.
Tags: advanced
study
response
immune
Merck Enters Strategic Collaborations with Amgen, Incyte and Pfizer to Evaluate Novel Combination Anti-cancer Regimens with MK-3475
2014-02-05 12:40:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. Merck Also to Initiate Phase I Signal Finding Study with MK-3475 in 20 New Cancer Types WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today it has signed three separate clinical collaboration agreements, through subsidiaries, with Amgen Inc., Incyte Corporation and Pfizer Inc. to evaluate novel combination regimens with MK-3475, Mercks investigational anti-PD-1 immunotherapy. The financial terms of the agreements were not disclosed. Language: English Contact: MerckMedia:Ian McConnell, 908-423-3046orClaire Mulhearn, 908-423-7425orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: with
combination
strategic
evaluate
Carmot Therapeutics Enters Into Drug Discovery Collaboration With Amgen
2014-02-05 07:26:04| drugdiscoveryonline News Articles
Carmot Therapeutics recently announced that it has entered into a collaboration and license agreement with Amgen, Inc. (Thousand Oaks, CA). During the collaboration Carmot will apply its proprietary Chemotype Evolution to discover novel drug leads for two targets selected by Amgen
Tags: drug
collaboration
discovery
enters
Sites : [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] next »